Login
News & Updation
Best Article Awards
World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.
Best Article of current issue
Download Article : Click here
Indexing
Abstract
TRANSFORMING THE MEDICAL LANDSCAPE: AN IN-DEPTH ANALYSIS OF THE ADVANCEMENTS IN PHARMACEUTICAL NANOMEDICINE
Sneha Kundu, Supratim Datta, Milan Kumar Maiti and *Partha Pratim Mahata
ABSTRACT
Nanotechnology is becoming more significant in the realms of medicine and medication delivery because traditional pharmaceutical agents and their antiquated formulations and delivery systems have serious limits. Since several nanotechnology applications have been created and a number of nanotechnology-based medications are currently available on the market, the impact of nanotechnology on healthcare is already being seen. The increasing number of drug candidates with poor solubility is reflected in the growing interest in drug nanoparticles and nano-cocrystals for research purposes; the primary use of these nanosystems is to increase solubility. Verifying these nanoparticles' lifetime functioning, the consistency of the formulation procedures, the produced systems' functional performance in a predetermined manner, and the systems' stability, it is vital to have a solid understanding of physic chemistry with the use of the appropriate analytical techniques. The bioavailability of a product can be affected by even minute variations in particle size, for instance, or size differences at the nanoscale. The Quality by design (QbD), which is defined by the FDA, is particularly useful for deciding on a stabilising agent and manufacturing process for pharmaceutical nanocrystals as well as determining Critical Quality Attributes (CQAs). The impact is amplified when dealing with the tiniest fractions of particles. Our goals were to assess the nanomedicines that have been given global market approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to briefly discuss the difficulties encountered during their development, and to consider potential future developments. In addition, a brief discussion will cover the significance of nanotechnology in the creation of pharmaceutical products, the ideal characteristics of nanocarriers, the causes of the failure of some nanomedicines, and the critical factors in the development of nanomedicines.
[Full Text Article] [Download Certificate]